Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Duloxetine
Drug ID BADD_D00734
Description Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.[A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.[L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Indications and Usage Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72.
Marketing Status Prescription
ATC Code N06AX21
DrugBank ID DB00476
KEGG ID D07880
MeSH ID D000068736
PubChem ID 60835
TTD Drug ID D01AXB
NDC Product Code 55700-605; 60760-461; 53002-1561; 50436-0198; 71610-403; 47335-383; 70518-3287; 71205-005; 0228-2890; 43547-381; 61919-422; 53002-1494; 71205-358; 46708-279; 70710-1539; 68788-7672; 43547-379; 63629-5174; 80425-0119; 47335-616; 70710-1537; 55154-4981; 68180-294; 65841-801; 55154-4980; 45865-816; 70518-1128; 46708-278; 46708-280; 63629-8748; 47335-382; 70710-1538; 49252-007; 68382-386; 71205-602; 70771-1345; 68084-692; 61919-483; 50090-4011; 50090-4709; 51655-237; 67877-263; 47335-618; 71205-445; 70771-1344; 68382-387; 71335-2017; 68788-7935; 27241-099; 50268-288; 68180-296; 65841-799; 71335-1672; 70518-1011; 31722-168; 0228-2892; 63629-5202; 67877-265; 68180-295; 27241-164; 65977-0035; 47335-381; 70518-1054; 60760-462; 50090-5940; 47335-619; 68382-385; 31722-169; 50268-287; 45865-813; 68084-683; 63629-8051; 70771-1346; 65841-800; 43547-380; 49252-008; 71205-525; 68071-4700; 50090-4708; 55700-628; 70518-2855; 68180-297; 47335-617; 70518-3177; 31722-581; 70518-1139; 31722-582; 27241-098; 49252-009; 27241-097; 55700-727; 71335-0402; 67877-264; 68788-7828; 31722-583; 71335-1964; 68084-675; 0228-2891; 50436-0199; 50268-286; 31722-170; 70518-2630
Synonyms Duloxetine Hydrochloride | Hydrochloride, Duloxetine | Duloxetine HCl | HCl, Duloxetine | LY 248686 | LY-248686 | LY248686 | Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987 | LY 227942 | LY-227942 | LY227942 | Duloxetine | N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide | N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine | Duloxetine, (+)-isomer | Cymbalta
Chemical Information
Molecular Formula C18H19NOS
CAS Registry Number 116539-59-4
SMILES CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastroenteritis viral11.05.04.005; 07.19.03.005--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Generalised anxiety disorder19.06.01.0040.000198%Not Available
Generalised oedema14.05.06.007; 08.01.07.004--
Generalised tonic-clonic seizure17.12.01.0020.000926%Not Available
Gestational diabetes18.02.04.001; 14.06.01.008; 05.06.01.0080.000198%Not Available
Glaucoma06.03.01.0020.000397%
Glomerular filtration rate decreased13.13.01.0090.000198%Not Available
Glossodynia07.14.02.001--Not Available
Haematemesis07.12.02.002; 24.07.02.011--Not Available
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Blood urine present13.13.02.002--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemorrhoids07.15.03.001; 24.10.02.002--
Hallucination19.10.02.0020.006417%
Hallucination, auditory19.10.02.0030.001588%Not Available
Hallucination, visual19.10.02.0040.001058%Not Available
Hangover08.01.09.0180.000132%Not Available
Head discomfort17.02.05.0270.000198%Not Available
Headache17.14.01.0010.117422%
Heart rate increased13.14.04.0020.001786%Not Available
Hemiparesis17.01.04.001--
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.006--Not Available
Hepatic failure09.01.03.002--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 26 Pages